CO2024008181A2 - Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteínas de fusión il-15 - Google Patents
Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteínas de fusión il-15Info
- Publication number
- CO2024008181A2 CO2024008181A2 CONC2024/0008181A CO2024008181A CO2024008181A2 CO 2024008181 A2 CO2024008181 A2 CO 2024008181A2 CO 2024008181 A CO2024008181 A CO 2024008181A CO 2024008181 A2 CO2024008181 A2 CO 2024008181A2
- Authority
- CO
- Colombia
- Prior art keywords
- fusion proteins
- antibodies
- antibody
- antigen
- binding fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284937P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/080542 WO2023102367A1 (en) | 2021-12-01 | 2022-11-29 | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024008181A2 true CO2024008181A2 (es) | 2024-06-27 |
Family
ID=84519919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0008181A CO2024008181A2 (es) | 2021-12-01 | 2024-06-24 | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteínas de fusión il-15 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312724A1 (https=) |
| EP (1) | EP4441093A1 (https=) |
| JP (1) | JP2024543942A (https=) |
| KR (1) | KR20240112342A (https=) |
| CN (1) | CN118339184A (https=) |
| AR (1) | AR127806A1 (https=) |
| AU (1) | AU2022402985A1 (https=) |
| CA (1) | CA3238965A1 (https=) |
| CO (1) | CO2024008181A2 (https=) |
| IL (1) | IL313159A (https=) |
| MX (1) | MX2024006573A (https=) |
| TW (1) | TW202346320A (https=) |
| WO (1) | WO2023102367A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US9422351B2 (en) * | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| AU2019228381B2 (en) * | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
-
2022
- 2022-11-29 CA CA3238965A patent/CA3238965A1/en active Pending
- 2022-11-29 AU AU2022402985A patent/AU2022402985A1/en active Pending
- 2022-11-29 MX MX2024006573A patent/MX2024006573A/es unknown
- 2022-11-29 IL IL313159A patent/IL313159A/en unknown
- 2022-11-29 KR KR1020247021496A patent/KR20240112342A/ko active Pending
- 2022-11-29 TW TW111145737A patent/TW202346320A/zh unknown
- 2022-11-29 US US18/059,548 patent/US20230312724A1/en active Pending
- 2022-11-29 AR ARP220103274A patent/AR127806A1/es unknown
- 2022-11-29 WO PCT/US2022/080542 patent/WO2023102367A1/en not_active Ceased
- 2022-11-29 EP EP22823298.9A patent/EP4441093A1/en active Pending
- 2022-11-29 JP JP2024532180A patent/JP2024543942A/ja active Pending
- 2022-11-29 CN CN202280079188.6A patent/CN118339184A/zh active Pending
-
2024
- 2024-06-24 CO CONC2024/0008181A patent/CO2024008181A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023102367A1 (en) | 2023-06-08 |
| TW202346320A (zh) | 2023-12-01 |
| JP2024543942A (ja) | 2024-11-26 |
| MX2024006573A (es) | 2024-06-11 |
| US20230312724A1 (en) | 2023-10-05 |
| EP4441093A1 (en) | 2024-10-09 |
| KR20240112342A (ko) | 2024-07-18 |
| IL313159A (en) | 2024-07-01 |
| AR127806A1 (es) | 2024-02-28 |
| AU2022402985A1 (en) | 2024-07-11 |
| CN118339184A (zh) | 2024-07-12 |
| CA3238965A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125427T1 (el) | Anti-gm-csf αντισωματα και χρησεις αυτων | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| CL2025002941A1 (es) | Anticuerpos anti-sirp-alfa. | |
| CL2019002717A1 (es) | Receptores de unión a antígeno mejorados. | |
| PE20211217A1 (es) | Anticuerpos estabilizadores de trem2 | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
| PE20091382A1 (es) | Anticuerpos que se une a il-4 y/o a il-13 | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| MX2022000988A (es) | Proteinas de union a antigeno anti-il13. | |
| PE20211792A1 (es) | Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| MX2021010281A (es) | Proteinas de enlace a antigenos que se enlazan al bcma. | |
| CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| UY39324A (es) | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| CO2023015859A2 (es) | Anticuerpos para tratar alfa-sinucleinopatías | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| UY38432A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| CO2024008181A2 (es) | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteínas de fusión il-15 | |
| CO2017007377A1 (es) | Antígenos recombinantes de giardia, purificación de anticuerpos policlonales igg e igy anti-giardia y detección de giardia |